We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 985

Study: top 5 healthcare investment priorities for U.S. states
  • McGuireWoods LLP
  • USA
  • February 3 2015

An analysis by Accenture of the State Health Innovation Plans developed by 25 states found the top five projected investment areas of the states


Weekly Washington healthcare update - December 15, 2014
  • McGuireWoods LLP
  • USA
  • December 15 2014

Congress Averts Government Shutdown By Passing Long-Term Funding Measure... Office of the National Coordinator for Health Information Technology


Biosimilars access and education taking center stage with first biosimilars in the wings
  • McGuireWoods LLP
  • USA
  • May 6 2015

Two new voices have emerged with goals to help expand patient access and information about biosimilars in the United Statesthe Biosimilars Forum and


FDLI’s 2015 Annual Conference educates a record crowd part two of two
  • McGuireWoods LLP
  • USA
  • April 28 2015

Continuing the Food and Drug Law Institute's (FDLI's) Annual Conference on April 20, 2015, a panel then discussed Data Integrity Compliance and


Republican HELP committee members request FDA to step up finalizing biosimilars guidances and transparency
  • McGuireWoods LLP
  • USA
  • May 7 2015

On April 30, 2015, Senators on the Health Education Labor and Pensions Committee (HELP) urged FDA to provide additional guidance on "important issues


Weekly Washington healthcare update - August 11, 2015
  • McGuireWoods LLP
  • USA
  • August 10 2015

Bipartisan Senate Letter Questions HHS and CMS on Details of State ACA Waivers...OMB Is Reviewing Final Medicaid-Covered Outpatient Drug Rule


Otsuka files amended complaint and motion for tropi for Abilify, pointing to Congressional intent to argue broad exclusivity
  • McGuireWoods LLP
  • USA
  • May 15 2015

As discussed in our April 13, 2015 blog, Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Development and Commercialization, Inc., and Otsuka


Compliance best practices for dental providers - recent OIG activity highlights need for robust compliance efforts
  • McGuireWoods LLP
  • USA
  • December 3 2014

As a result of the actions of a very small minority of the dental industry, dental support organizations (DSOs) have come under increasing


EEOC publishes proposed rule on how the ADA applies to employer wellness programs
  • McGuireWoods LLP
  • USA
  • April 23 2015

Many employers offer corporate wellness programs to promote healthier lifestyles, prevent disease and reduce healthcare costs. These wellness


New York AG accuses pharmaceutical companies of product hopping
  • McGuireWoods LLP
  • USA
  • October 7 2014

On September 15, in New York v. Actavis PLC et al., New York State Attorney General Eric Schneiderman filed an antitrust suit against Actavis PLC and